Skip to main content
Top
Published in: Current Hypertension Reports 2/2001

01-03-2001

Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease

Authors: Eiji Kubota, MD, Rachael G. Dean, BSc, PhD, Richard A. Hubner, BMBCh, Leanne C. Balding, MD, FRACP, Colin I. Johnston, MD, FRACP, Louise M. Burrell, MBChB, MD, FRACP

Published in: Current Hypertension Reports | Special Issue 2/2001

Login to get access
Metadata
Title
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease
Authors
Eiji Kubota, MD
Rachael G. Dean, BSc, PhD
Richard A. Hubner, BMBCh
Leanne C. Balding, MD, FRACP
Colin I. Johnston, MD, FRACP
Louise M. Burrell, MBChB, MD, FRACP
Publication date
01-03-2001
Publisher
Current Medicine Group
Published in
Current Hypertension Reports / Issue Special Issue 2/2001
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-001-0105-8

Other articles of this Special Issue 2/2001

Current Hypertension Reports 2/2001 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine